Diabetic ketoacidosis (DKA) remains one of the most dangerous acute complications of diabetes, and its direct link to missed or insufficient insulin doses is a critical area of focus for clinicians, patients, and caregivers. When insulin is omitted—whether due to oversight, access barriers, or psychological factors—the body’s metabolic balance rapidly deteriorates, triggering a cascade of events that can culminate in life-threatening acidosis. Understanding this relationship is essential for prevention, early recognition, and effective intervention.

The omission of insulin, even for a single dose in type 1 diabetes, can provoke DKA within hours under certain conditions. In type 2 diabetes, DKA is less common but can occur when insulin secretion is severely impaired or when insulin therapy is abruptly stopped. The core mechanism involves unopposed counter-regulatory hormone activity—glucagon, cortisol, catecholamines—which accelerates lipolysis and ketogenesis. This article explores the physiological pathways, clinical consequences, and practical strategies for mitigating the risks associated with insulin omission.

Physiology of Insulin and Glucose Regulation

Insulin is the primary anabolic hormone responsible for facilitating glucose entry into muscle, adipose tissue, and the liver. It suppresses hepatic glucose production, promotes glycogen synthesis, and inhibits lipolysis and ketogenesis. In the absence of adequate insulin, cells cannot utilize circulating glucose, leading to hyperglycemia. Simultaneously, the liver perceives a state of energy deficit and begins producing ketone bodies—acetoacetate, beta-hydroxybutyrate, and acetone—as alternative fuel sources.

Under normal circumstances, ketone production is tightly regulated. However, when insulin deficiency is profound and prolonged, ketone concentrations exceed the body’s ability to excrete or buffer them, resulting in metabolic acidosis. The accumulation of ketones, combined with hyperglycemia-induced osmotic diuresis, leads to severe dehydration, electrolyte imbalances, and eventually altered mental status. For a comprehensive overview of insulin physiology, the NCBI Bookshelf provides an excellent resource on insulin action.

The Pathophysiology of DKA

DKA is characterized by three cardinal features: hyperglycemia (usually >250 mg/dL), metabolic acidosis (pH <7.3, bicarbonate <15 mEq/L), and ketonemia or ketonuria. The sequence begins with insulin deficiency or resistance. Without insulin, glucagon levels rise sharply, stimulating glycogenolysis and gluconeogenesis in the liver. The resulting hyperglycemia overwhelms the renal reabsorptive capacity, causing glycosuria and osmotic diuresis. This leads to volume depletion and electrolyte losses—especially sodium, potassium, and phosphate.

Concurrent with hyperglycemia, increased lipolysis releases free fatty acids into the circulation. The liver oxidizes these fatty acids to acetyl-CoA, which is then converted into ketone bodies. Beta-hydroxybutyrate is the dominant ketone in DKA and is a strong organic acid. As ketone levels rise, the buffering capacity of bicarbonate is exhausted, and arterial pH drops. The body attempts to compensate by increasing respiratory rate, resulting in Kussmaul breathing—deep, rapid respirations that expel carbon dioxide. If untreated, progressive acidosis impairs cellular function, leading to coma and death.

Role of Insulin Omission in Triggering DKA

Insulin omission is the most common precipitating factor for DKA in individuals with established diabetes. Studies have shown that a significant proportion of DKA episodes occur in patients who report skipping insulin doses within the preceding 24 hours. The risk is highest in type 1 diabetes because even short lapses in basal insulin (such as a missed long-acting dose) can precipitate ketosis. In type 2 diabetes, DKA often presents with a milder hyperglycemia and is termed “ketosis-prone” or “Flatbush” diabetes, but the underlying etiology remains similar—functional insulin deficiency.

The duration of insulin absence directly correlates with DKA severity. A single missed dose may not always cause DKA if the patient has some residual beta-cell function or is using adjunctive insulin-sensitizing medications. However, in patients with little to no endogenous insulin production, even six hours without enough insulin can lead to ketone buildup. The American Diabetes Association provides clinical guidelines on DKA prevention that emphasize consistent insulin adherence as the cornerstone of risk reduction.

Common Causes and Risk Factors for Insulin Omission

Understanding why patients omit insulin is critical for designing interventions. The reasons are diverse and often multifactorial.

Forgetfulness and Missed Doses

Busy lifestyles, irregular schedules, and lack of routine can lead to accidental omissions. Patients on multiple daily injection regimens or continuous subcutaneous insulin infusion may inadvertently skip or delay doses. Memory cues, phone alarms, and insulin diary apps can mitigate this, but systematic lapses remain common.

Cost and Access Barriers

Insulin affordability is a significant global issue. Many patients ration their doses to stretch a limited supply, especially in healthcare systems with high out-of-pocket costs. This practice dramatically increases DKA risk. The FDA’s approval of generic insulin products has helped, but cost remains a barrier for many.

Misunderstanding of Dosage Requirements

Some patients reduce or skip doses because they misinterpret blood glucose levels or fear hypoglycemia. For example, patients may skip a correction dose if they feel well, without recognizing that ketones may already be accumulating. Lack of ketone testing supplies further compounds this knowledge gap.

Intentional Non-Compliance and Psychological Factors

Insulin omission can be intentional due to body image concerns (diabulimia), a desire to lose weight, or emotional burnout. This is particularly prevalent among adolescents and young adults with type 1 diabetes. Psychological support, diabetes education, and screening for eating disorders are essential components of care.

Technical Issues with Insulin Delivery

Pump failures, infusion set occlusions, and insulin pen malfunctions can lead to unnoticed insulin omission. Patients using insulin pumps should have a backup plan and be educated on how to check for ketones when unexplained hyperglycemia occurs. The CDC offers practical tips for managing diabetes devices to reduce the risk of DKA.

Symptomatology of DKA Arising from Insulin Omission

The presentation of DKA varies with the degree of insulin deficiency, volume status, and patient age. Symptoms often develop over a few hours to days, but in the context of complete insulin omission (e.g., after a pump failure), onset can be rapid.

Early Symptoms

  • Polyuria and polydipsia: Hyperglycemia causes osmotic diuresis, leading to frequent urination and compensatory thirst.
  • Blurred vision: Osmotic changes in the lens due to glucose fluctuations.
  • Fatigue and weakness: Inefficient glucose utilization and impending acidosis.

Progressive Symptoms

  • Nausea, vomiting, and abdominal pain: Gastroparesis and electrolyte disturbances contribute. Abdominal pain can be severe and mimic acute surgical abdomen.
  • Kussmaul breathing: Deep, rapid respirations; a compensatory respiratory alkalosis to counteract metabolic acidosis.
  • Fruity or acetone-like breath odor: Due to exhaled ketones, particularly acetone.
  • Dehydration: Dry mucous membranes, decreased skin turgor, tachycardia, orthostatic hypotension.

Late and Severe Symptoms

  • Altered mental status: Confusion, drowsiness, obtundation, coma. Cerebral edema is a rare but fatal complication, especially in children.
  • Shock and anuria: Severe volume depletion can lead to prerenal failure.

Any patient with suspected DKA requires immediate assessment of fingerstick glucose, serum electrolytes, venous pH, and blood or urine ketones. The severity of acidosis (pH <7.0 or bicarbonate <5 mEq/L) indicates impending critical illness.

Diagnostic Evaluation and Clinical Pearls

DKA diagnosis is straightforward but must be considered in any patient with known diabetes presenting with hyperglycemia and acidosis. Key laboratory findings include:

  • Blood glucose >250 mg/dL (though euglycemic DKA occurs with SGLT2 inhibitor use).
  • pH <7.3 (venous or arterial).
  • Bicarbonate <15 mEq/L.
  • Anion gap >10–12 mEq/L.
  • Positive serum ketones (beta-hydroxybutyrate >0.6 mmol/L).

Bedside point-of-care ketone meters are valuable for early detection. Patients should be taught to check ketones whenever ill, or when blood glucose >300 mg/dL for more than two consecutive readings. The Endocrine Society’s clinical practice guidelines for DKA management stress the importance of identifying precipitating factors, with insulin omission as a primary consideration.

Complications of Delayed Treatment

Untreated DKA progresses to life-threatening complications. Hypokalemia often develops as insulin therapy drives potassium into cells; careful monitoring is essential. Cerebral edema is a particular risk in pediatric DKA and is associated with rapid osmolar shifts—thus, fluids should be administered cautiously. Acute respiratory distress syndrome, disseminated intravascular coagulation, and acute kidney injury can occur in severe cases. Mortality rates for DKA remain under 1% in specialized centers but rise with delayed presentation.

Prevention: Addressing Insulin Omission at the Root

Preventing DKA requires a multifaceted approach that addresses the underlying reasons for insulin omission.

Patient Education and Self-Management

Structured diabetes education is paramount. Patients must understand the connection between insulin omission and DKA, recognize early symptoms, and know sick-day rules. This includes instructions to never completely stop insulin even during vomiting—instead, they should adjust doses under medical guidance. Provision of ketone testing supplies and a written action plan reduces delay in care.

Technology and Monitoring

Continuous glucose monitors (CGM) with trend alarms can alert patients to rapid glucose elevation, prompting earlier screening for ketones. Insulin pump users benefit from high- and low-glucose alarms and automated insulin suspension features (e.g., predictive low-glucose suspend). Remote monitoring by caregivers or clinicians can also flag prolonged hyperglycemia.

Psychosocial Support

Identifying and addressing intentional insulin omission requires non-judgmental dialogue during clinic visits. Screening for diabetes distress, depressive symptoms, and disordered eating using validated tools should be standard. Referral to mental health professionals with expertise in diabetes is beneficial.

System-Level Interventions

Healthcare systems should ensure affordable access to insulin, syringes/pen needles, and ketone strips. Policy initiatives to cap insulin copays and expand production of biosimilar insulin have shown promise in reducing rationing. Pharmacist-led interventions—such as automatic refills and medication synchronization—can reduce missed doses.

Management of Established DKA

Hospital management of DKA involves three key components: fluid resuscitation, insulin therapy, and electrolyte correction.

  1. Fluid replacement: Start with isotonic saline (0.9% NaCl) at 15–20 mL/kg per hour in the first hour, then adjust based on hemodynamic status. Replace free water deficit over 24–48 hours to avoid cerebral edema.
  2. Insulin therapy: Regular insulin IV at 0.1 unit/kg bolus followed by 0.1 unit/kg/hour continuous infusion. Aim for a decline in glucose of 50–75 mg/dL per hour. Once glucose reaches 200–250 mg/dL, add dextrose-containing fluids and reduce insulin rate to prevent hypoglycemia while correcting ketosis.
  3. Potassium replacement: Monitor potassium closely. Initiate replacement when levels fall below 5.3 mEq/L (or higher if earlier in presence of electrocardiographic changes). Goal is to maintain K+ between 4.0–5.0 mEq/L.
  4. Bicarbonate: Generally avoided unless pH <6.9 due to risk of paradoxical cerebral acidosis.

Transition to subcutaneous insulin after resolution of acidosis (pH >7.3, bicarbonate >18 mEq/L, anion gap normal). Overlap intravenous and subcutaneous doses to prevent rebound DKA.

Special Populations and Considerations

Children and Adolescents

DKA in children is often the first presentation of type 1 diabetes. A high index of suspicion is needed for enuresis, weight loss, and behavioral changes. Cerebral edema is more common in this age group, so careful fluid management and avoidance of rapid correction are critical.

Pregnancy

Pregnant women with pre-existing type 1 diabetes are at increased DKA risk due to accelerated starvation and hormonal changes. Insulin omission during pregnancy can harm both mother and fetus, including intrauterine growth restriction and neurodevelopmental effects. Management must be aggressive to prevent fetal acidosis.

Elderly and Frail Patients

Atypical presentations—such as altered mental status or infection without ketoacidosis-suggesting symptoms—may delay diagnosis. Insulin omission in this group often stems from cognitive decline or polypharmacy conflicts. Simplified regimens (e.g., fixed-dose combination insulin) may improve adherence.

Conclusion

The relationship between insulin omission and DKA is direct, mechanistic, and potentially catastrophic. Each missed dose is an opportunity for metabolic derangement. Addressing insulin omission requires recognizing its multifactorial causes—ranging from accidental forgetfulness to intentional avoidance—and implementing targeted prevention strategies at the patient, clinician, and system levels. With adequate education, accessible tools, and compassionate support, many DKA episodes can be prevented. Early recognition and timely management of DKA remain critical for saving lives and reducing long-term diabetes complications.

For further reading, the Diabetes UK guide on diabetic ketoacidosis provides patient-oriented information, while the NCBI review on DKA pathophysiology offers deeper mechanistic insights.